ESTRO 2024 - Abstract Book

S708

Clinical - Breast

ESTRO 2024

phenotype, 1 HER-2+ and another TN. With the exception of TN patient, all maintain hormone therapy. Two patients underwent 6 months of chemotherapy after the diagnoses of oligometastatic disease. No grade 3 or superior acute toxicities were noticed. Late toxicities include fibrosis on imagiological control in 2 patients treated for lung metastases, without functional impairment; a vertebral body collapse and a schmorl nodule were diagnosed in 2 patients treated for vertebral metastases.

Conclusion:

Our analysis confirmed the limited efficacy of local ablative radiotherapy in oligometastatic breast cancer. In appropriately selected patients, local treatment has a low toxicity profile and may improve clinical outcome, prolonging progression free survival allowing chemotherapy suspension. However, it appears that breast cancer is a systemic disease, with increasing difficulty in identifying purely oligometastatic disease. Further prospective studies are needed to determine the patient selection criteria for local treatment.

Keywords: oligometastases, ablative radiotherapy

References:

Chmura S.J., Winter K.A., Woodward W.A., Borges V.F., Salama J.K., Al-Hallaq H.A., Matuszak M., Milano M.T., Jaskowiak N.T., Bandos H., et al. A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557) J. Clin. Oncol. 2022;40:1007. doi: 10.1200/JCO.2022.40.16_suppl.1007. Thomssen C, Balic M, Harbeck N, Gnant M. St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer. Breast Care (Basel). 2021 Apr;16(2):135-143. doi: 10.1159/000516114.

2997

Digital Poster

Comprehensive cosmesis evaluation of ultrahypofractionated adjuvant breast radiotherapy with SIB

Tabassum Wadasadawala 1 , Shraddha Kenekar 1 , Rajiv Sarin 1 , Rima Pathak 1 , Revathy Krishnamurthy 1 , Vani Parmar 2 , Nita Nair 3 , Shalaka Joshi 4 , Akash Pawar 5 , Naseera Syeda 1 , Sonal Chavan 1 , Manisha Kohle 1 1 Tata Memorial Centre, Homi Bhabha National Institute, Radiation Oncology, Mumbai, India. 2 Punyashlok Ahilyadevi Holkar Head Neck Institute of India, Surgical Oncology, Mumbai, India. 3 Apollo Hospital, Surgical Oncology, Mumbai, India. 4 Tata Memorial Centre, Homi Bhabha National Institute, Surgical Oncology, Mumbai, India. 5 Tata Memorial Centre, Homi Bhabha National Institute, Statistics, Mumbai, India

Purpose/Objective: